The grades of four Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Johnson & Johnson (NYSE:JNJ) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Equity, JNJ also gets A’s. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb (NYSE:BMY) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. Shares of BMY have increased 8.9% over the past month, better than the 0.6% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BMY stock.
The rating of Watson Pharmaceuticals (NYSE:WPI) moves up this week, rising from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Repros Therapeutics’ (NASDAQ:RPRX) ratings are up from a B last week to an A. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 7.7% over the past month. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.